Intracavernosal Injection: Process, Uses, and Side Effects

Intracavernosal injection therapy involves injecting a vasodilating medication directly into the shaft of the penis to produce an erection, and it remains one of the most reliable treatments for erectile dysfunction when oral medications fall short. The drug relaxes smooth muscle inside the erectile tissue, allowing blood to rush in and fill the chambers that create rigidity. The technique has been in clinical use since the early 1980s and serves both as a treatment and as a diagnostic tool, yet it comes with a unique set of practical demands and potential complications that anyone considering it should understand before their first office visit.

How the Injection Produces an Erection

A normal erection depends on blood flowing into two spongy cylinders of tissue, the corpora cavernosa, that run the length of the penis. That inflow is controlled by smooth muscle cells lining the arterial walls and the tissue itself. When those muscles relax, arteries widen, blood pools inside the corpora, and the expanding tissue compresses the veins that would normally drain blood away. The result is rigidity. In many forms of erectile dysfunction, the signaling chain that triggers this relaxation is broken somewhere along the way, whether by nerve damage, vascular disease, or other causes.

Intracavernosal injection bypasses all of that signaling by delivering a vasodilator straight to the smooth muscle. The medication acts locally, so it does not depend on sexual arousal, intact nerves, or a functioning hormonal cascade to work. As one review describes the mechanism, the vasodilators are “directly injected into the cavernous body of the penis, resulting in smooth muscle relaxation and engorgement of the corpora cavernosa with blood.”¹ An erection typically begins within five to fifteen minutes and can last long enough for intercourse.

Who Uses It and Why

For most men with erectile dysfunction, oral PDE5 inhibitors like sildenafil or tadalafil are the first thing a doctor prescribes. Intracavernosal injection is considered a second-line treatment, meaning it enters the picture when pills do not work well enough, cause intolerable side effects, or are medically contraindicated. One large group that frequently relies on injection therapy is men who have had a radical prostatectomy for prostate cancer. The surgery often damages the nerves responsible for erections, and oral medications may not compensate adequately. In that population, injection therapy, transurethral alprostadil, and vacuum devices have all been shown to be highly effective.²

A study of post-prostatectomy patients at a single center found that about half continued actively using injection therapy, and among those users, nearly all (98%) remained sexually active compared with just over a third of the men who stopped. Users also reported significantly better erectile function scores.³ The therapy also works for men whose erectile dysfunction stems from diabetes, cardiovascular disease, spinal cord injury, or psychological causes. In a trial of 67 men who had failed sildenafil, about 90% saw improvement in their ability to achieve and maintain erections after switching to injectable alprostadil.⁴

The Medications Involved

Several drugs are used for intracavernosal injection, either alone or in combination. The most widely used single agent is alprostadil, a synthetic form of prostaglandin E1. It is available as FDA-approved branded products and also through compounding pharmacies. A landmark dose-response trial of 296 men established that alprostadil’s effectiveness climbs with dose, with response rates increasing across doses ranging from 2.5 to 20 micrograms. The minimum effective dose varied by the cause of dysfunction: men with neurogenic causes often responded to very low doses, while those with vascular causes typically needed more.⁵

When alprostadil alone is not enough, clinicians often turn to combination formulations. The best known is “trimix,” a compounded blend of alprostadil, papaverine, and phentolamine. Each component works through a slightly different pathway, so together they can produce a stronger response at lower individual doses, which tends to reduce side effects. A prospective study found that a small dose of trimix was more sensitive than a standard dose of alprostadil alone for both diagnosing and treating erectile dysfunction.⁶ A newer combination pairs aviptadil (a vasoactive intestinal polypeptide) with phentolamine, though it is less commonly used.⁷

What the Procedure Actually Looks Like

Nobody starts injecting at home without supervised training. The standard protocol begins in a clinician’s office, where the dose is carefully adjusted upward across one or more visits until the response is adequate but not excessive. This titration process is essential because the wrong dose can cause a prolonged erection that becomes a medical emergency. Only after a safe and effective dose has been identified does the patient learn to self-inject.⁸

For self-injection, the needle is very fine, similar to an insulin syringe. The injection site is on the lateral (side) surface of the penile shaft, roughly at the midpoint. Injecting into the top or bottom of the penis is avoided because of the major blood vessels and the urethra running in those locations. Most doctors instruct patients to alternate sides with each injection and to vary the exact spot slightly so that no single area accumulates too much needle trauma. The injection itself is quick. In a study that measured pain during the first injection, about 70% of men reported no pain or only mild pain, though roughly one in ten described it as severe.⁹ Pain perception tends to decrease with experience as men become more comfortable with the technique.

Injections as a Diagnostic Tool

Intracavernosal injection is not only a treatment. Urologists also use it during diagnostic workups to figure out what is causing a man’s erectile dysfunction. The most common application is in combination with penile Doppler ultrasound, a type of imaging that measures blood flow. After injecting a vasodilator to induce an erection, the clinician uses ultrasound to observe how blood flows into and out of the penis. This helps distinguish between arterial insufficiency (not enough blood flowing in), venous leak (blood draining away too fast), and non-vascular causes.¹⁰

The diagnostic value of this combination is well established. One review concluded that injection-assisted Doppler ultrasound helps detect penile vascular abnormalities and allows clinicians to differentiate among various vascular causes of impotence, guiding them toward the best treatment for each patient.¹¹ If you undergo an evaluation for erectile dysfunction at a urology clinic, there is a good chance an injection-assisted ultrasound will be part of the assessment.

Side Effects and Risks

The side effect profile of intracavernosal injection therapy is distinct from what you would expect with oral medications. The risks are mostly local to the penis, though a couple have systemic implications.

Penile Pain

Some degree of aching or burning at the injection site or within the shaft is the most frequently reported complaint. As noted above, about 30% of men experience moderate to severe pain during their first injection.⁹ Alprostadil in particular can cause an aching sensation within the penis that is separate from needle pain, a side effect related to the drug’s prostaglandin activity. Combination formulations like trimix sometimes reduce this because the alprostadil dose can be lowered.

Priapism

Priapism, an erection that lasts more than four hours and will not subside, is the most serious acute risk. It constitutes a medical emergency because prolonged engorgement starves the tissue of oxygenated blood and can cause permanent damage. Historically, papaverine carried the highest risk of priapism among the injectable agents, and this concern reshaped its clinical use over time.⁷ If priapism does occur, the immediate treatment is aspiration (draining blood from the corpora with a needle) and injection of phenylephrine, a vasoconstrictor. Surgical intervention may be necessary in prolonged or recurrent cases.⁸

An analysis of patients presenting with priapism after injection therapy found that younger men were at considerably higher risk, as were those with mood disorders, behavioral disorders, and sickle cell disease.¹² Proper dose titration in the office is the main safeguard; patients are also told to seek emergency care if an erection persists beyond four hours.

Penile Fibrosis

Long-term use can lead to the formation of scar tissue (fibrosis) within the penis, particularly at or near injection sites. In a study of 245 men returning for repeat prescriptions of alprostadil, roughly 23% were found to have penile fibrosis on examination.¹³ Earlier case reports had documented curvature deformity and fibrosis of the tunica albuginea (the tough membrane surrounding the erectile tissue) in men who self-injected papaverine and phentolamine over long periods.¹⁴ Fibrosis can reduce the effectiveness of injections over time and may cause pain or visible curvature. Rotating the injection site is the primary preventive measure; if the same spot is used repeatedly, the risk climbs substantially.

Bleeding and Bruising

Minor bruising or a small hematoma at the injection site is relatively common and usually harmless. A question that comes up often is whether men on blood-thinning medications face extra risk. A pilot study compared bleeding complications between men on anticoagulants and those not on anticoagulants. While there were numerically more bleeding events in the anticoagulant group (about 7% versus 0%), the difference did not reach statistical significance, and the events were minor.¹⁵ Most clinicians do not consider anticoagulant use a firm contraindication, though they may advise extra care with injection technique and applying pressure afterward.

Why So Many Men Stop

One of the most striking features of intracavernosal injection therapy is the dropout rate. Despite its effectiveness, a large proportion of men who start therapy eventually abandon it. In one long-term follow-up, 40% of patients who began home self-injection discontinued within an average of about seven months. The main reasons were dissatisfaction with the process, cost, and erections that were not firm enough for penetration.¹⁶

A more recent study from the era of PDE5 inhibitors found an even steeper decline: nearly 80% of patients eventually discontinued. The leading reason was poor response (43%), followed by inconvenience (18%), switching to other treatments (11%), and loss of libido (about 7%). Only a small fraction stopped because of adverse events (roughly 6%), and an even smaller number quit because their erections had returned on their own.¹⁷ Post-prostatectomy data show a similar pattern, with about half of men discontinuing over time.³

The takeaway is not that the therapy fails most users, but that it asks a lot. Psychologically, injecting your own penis before sex is a high bar. Practically, the medication needs to be stored properly, the injection technique needs to be consistent, and the timing has to be planned. For men who stay with it, though, satisfaction tends to be meaningful. In one study, intercourse satisfaction scores roughly tripled from baseline, and attaining a fully rigid erection was the strongest predictor of overall satisfaction.¹⁸

Storing and Handling the Medications

If you are using a compounded trimix formulation, storage matters more than you might expect. Alprostadil is the least stable of the three components. At room temperature, about 8% of the alprostadil degrades within five days. Under refrigeration, losses reach about 6% after one month and about 11% after two months. Frozen at standard freezer temperatures, less than 5% of any component is lost over six months.¹⁹ The practical guidance that follows from this: keep the vial frozen if you are not going to use it within a few weeks, thaw only what you plan to use soon, and refrigerate the active vial. Minimize the time it sits at room temperature. If you are using a branded alprostadil product that comes as a powder to reconstitute, the shelf life after mixing is typically shorter still and should follow the package directions closely.

What It Costs

Injection therapy is not cheap, especially if you are paying out of pocket. A Medicare cost modeling analysis estimated that a year of intracavernosal injection therapy runs about $3,947 in patient out-of-pocket costs, making it one of the most expensive ongoing treatments for erectile dysfunction. For comparison, a year of oral PDE5 inhibitor medication came in at roughly $696, and a vacuum erection device was around $213 as a one-time expense. Only intraurethral alprostadil was slightly more expensive than injection at about $4,022 per year.²⁰ Medicare has no published national coverage policy for intracavernosal injection, meaning coverage varies and many men bear the full cost. Compounded trimix can be less expensive than branded alprostadil products, but the cost still adds up with regular use.

Needle-Free Devices and Future Directions

For men who could benefit from injection therapy but cannot get past needle phobia, needle-free injection devices represent an evolving alternative. These devices use high-pressure mechanisms to push fluid through the skin without a traditional needle. Early versions performed poorly compared with standard syringes, but engineering advances have improved their delivery reliability. Cadaver research has demonstrated that modern needle-free injectors can successfully deposit medication into the corpora cavernosa, suggesting they could be a viable option for men who refuse or drop out of conventional injection therapy due to needle aversion.²¹ Clinical adoption remains limited, but the technology is worth asking about if standard injection is a nonstarter for you.

A Brief History of the Technique

The origins of intracavernosal injection therapy are colorful. The French vascular surgeon Ronald Virag reported that injecting papaverine into the penis could produce an erection in 1982. The following year, British physiologist Giles Brindley demonstrated the concept in perhaps the most memorable presentation in urology history, reportedly injecting himself before a live audience at a medical conference. Further refinements came quickly: the papaverine-phentolamine combination arrived in 1985, and prostaglandin E1 entered the picture in 1986. Over the next decade, alprostadil became the workhorse drug, and trimix formulations evolved to reduce side effects. Papaverine’s higher priapism risk gradually shifted clinical preference toward alprostadil-based regimens.⁷ Despite the arrival of oral PDE5 inhibitors in 1998, injection therapy never disappeared. It filled a niche that pills could not cover and continues to occupy that role today.